Not all patients with the same cancer respond equally well to therapy. At the MHH you will receive a special molecular tumor diagnosis.

Even if two people have the same cancer from a clinical point of view, the genetic changes in the tumor can be very different. Therefore, not all patients respond equally well to therapy. At the MHH, people who are seriously ill with cancer receive special molecular tumor diagnostics. Based on the molecular analyses, an interdisciplinary team of experts in a Molecular Tumor Board (MTB) advises on new therapeutic approaches for those affected for whom guideline treatments are missing or for which the previous treatment was unsuccessful.

Experts in oncology and the respective organ centers, as well as pathology, molecular pathology and biology, genetics and bioinformatics come together in the MTB. “Our goal is to work together for each patient to develop the best possible, individual therapy recommendation based on the current state of medical science,” explains Professor Dr. Arndt Vogel, Head of MTB at the Comprehensive Cancer Center (CCC).

Off-label treatment offers opportunities

If possible, the team of experts recommends inclusion in a suitable clinical study. In the case of rare and serious cancers, however, so-called off-label treatment is becoming increasingly common. This means that a drug for the treatment of the tumor has not yet been approved, but offers those affected the chance to alleviate their suffering. “Together with other top oncological centers in Germany, we document the course of therapy within the German Network for Personalized Medicine,” explains Professor Vogel. “The knowledge gained in this way generates additional evidence for new therapy concepts and thus simplifies our future therapy decisions.”

External partners also have the opportunity to introduce their patients to the MHH in the MTB. A virtual, data protection-compliant tumor board conference system enables you to participate in the conference remotely via video.